-
Subject Areas on Research
-
A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder.
-
A brief cognitive assessment tool for schizophrenia: construction of a tool for clinicians.
-
A cognitive investigation of schizophrenic delusions.
-
A follow-up study of post partum illness, 1946-1978.
-
A national study of violent behavior in persons with schizophrenia.
-
A pen-and-paper human analogue of a monkey prefrontal cortex activation task: spatial working memory in patients with schizophrenia.
-
A pilot study of a structured interview addressing sexual function in men with schizophrenia.
-
A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder.
-
A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.
-
A randomized, placebo-controlled study investigating the nicotinic α7 agonist, RG3487, for cognitive deficits in schizophrenia.
-
A trial of compliance therapy in outpatients with schizophrenia or schizoaffective disorder.
-
Abbreviated neuropsychological assessment in schizophrenia: prediction of different aspects of outcome.
-
Abnormal resting regional cerebral blood flow patterns and their correlates in schizophrenia.
-
Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance use disorders among adults with schizophrenia.
-
Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.
-
Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder.
-
Alternative pathways to violence in persons with schizophrenia: the role of childhood antisocial behavior problems.
-
An emerging schizophrenic syndrome.
-
Anticipated Benefits of Care (ABC): psychometrics and predictive value in psychiatric disorders.
-
Anticipating DSM-V: opportunities and challenges for cognition and psychosis.
-
Antipsychotic drug effects on brain morphology in first-episode psychosis.
-
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
-
Assertive community treatment: an update of randomized trials.
-
Association between genetic variation at the porphobilinogen deaminase gene and schizophrenia.
-
Attentional functioning in schizotypal personality disorder.
-
Attentional markers of vulnerability to schizophrenia: performance of medicated and unmedicated patients and normals.
-
Barriers to employment for people with schizophrenia.
-
Baseline neurocognitive deficits in the CATIE schizophrenia trial.
-
Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia.
-
Brief assessment of cognition in schizophrenia: normative data in an English-speaking ethnic Chinese sample.
-
Brief assessment of cognition in schizophrenia: validation of the Japanese version.
-
CMINDS does not have identical tests to the CATIE and MATRICS batteries. Commentary on O'Halloran et al.
-
COMT158 polymorphism and hostility.
-
Can IQ moderate the response to cognitive remediation in people with schizophrenia?
-
Cardiovascular response during a word association test and an interview.
-
Cerebral blood flow responses to inhaled carbon dioxide in schizophrenia.
-
Changes in cerebral blood flow and mental state after amphetamine challenge in schizophrenic patients.
-
Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care.
-
Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial.
-
Characteristics of very poor outcome schizophrenia.
-
Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature.
-
Circadian rhythms in cognitive functioning among patients with schizophrenia: impact on signal detection in clinical trials of potential pro-cognitive therapies.
-
Circumstances under which practice does not make perfect: a review of the practice effect literature in schizophrenia and its relevance to clinical treatment studies.
-
Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings.
-
Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far?
-
Clozapine decreases smoking in patients with chronic schizophrenia.
-
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).
-
Clozapine-induced electroencephalogram changes as a function of clozapine serum levels.
-
Clues to the cognitive and perceptual origins of social isolation and psychosis in schizophrenia.
-
Cognition and motivation as treatment targets in schizophrenia.
-
Cognition as an outcome measure in schizophrenia.
-
Cognitive Decline and Disrupted Cognitive Trajectory in Schizophrenia.
-
Cognitive burden of anticholinergic medications in psychotic disorders.
-
Cognitive disparity in schizophrenics with and without cocaine dependency.
-
Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia.
-
Cognitive function and biological correlates of cognitive performance in schizotypal personality disorder.
-
Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer's disease.
-
Cognitive impairment as a target for pharmacological treatment in schizophrenia.
-
Cognitive impairment in schizophrenia.
-
Common sense, insight, and neuropsychological test performance in schizophrenia patients.
-
Community adjustment of older schizophrenics.
-
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
-
Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia.
-
Comprehensive model of how reality distortion and symptoms occur in schizophrenia: could impairment in learning-dependent predictive perception account for the manifestations of schizophrenia?
-
Converting positive and negative symptom scores between PANSS and SAPS/SANS.
-
Convulsive threshold differences in right unilateral and bilateral ECT.
-
Correlates of Future Violence in People Being Treated for Schizophrenia.
-
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
-
Countertransference in the expectant father.
-
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.
-
Defining a cognitive function decrement in schizophrenia.
-
Demographics, family history, premorbid functioning, developmental characteristics, and course of patients with deteriorated affective disorder.
-
Determining when impairment constitutes incapacity for informed consent in schizophrenia research.
-
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function.
-
Development of a virtual reality assessment of everyday living skills.
-
Diagnostic issues in chronic schizophrenia: kraepelinian schizophrenia, undifferentiated schizophrenia, and state-independent negative symptoms.
-
Disrupted network cross talk, hippocampal dysfunction and hallucinations in schizophrenia.
-
Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial.
-
Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data.
-
Dysregulation of DGCR6 and DGCR6L: psychopathological outcomes in chromosome 22q11.2 deletion syndrome.
-
ECT stimulus intensity: are present ECT devices too limited?
-
Effect of ECT treatment number on the ictal EEG.
-
Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.
-
Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.
-
Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
-
Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
-
Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials.
-
Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.
-
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
-
Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia.
-
Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.
-
Effects of glutamate positive modulators on cognitive deficits in schizophrenia: a systematic review and meta-analysis of double-blind randomized controlled trials.
-
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
-
Effects of β-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-Like Behavior in Hypoglutamatergic Mice.
-
Empirical assessment of the factorial structure of clinical symptoms in schizophrenia: negative symptoms.
-
Empirical assessment of the factorial structure of clinical symptoms in schizophrenic patients: formal thought disorder.
-
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale.
-
Establishing the Brief Assessment of Cognition - Short form.
-
Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort.
-
Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial.
-
Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis.
-
Eye tracking, attention, and schizotypal symptoms in nonpsychotic relatives of patients with schizophrenia.
-
Failures in learning-dependent predictive perception as the key cognitive vulnerability to psychosis in schizophrenia.
-
Familial schizophrenia and treatment response.
-
Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.
-
Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
-
Further Advances in Optimizing (2-Phenylcyclopropyl)methylamines as Novel Serotonin 2C Agonists: Effects on Hyperlocomotion, Prepulse Inhibition, and Cognition Models.
-
Heritability of functioning in families with schizophrenia in relation to neurocognition.
-
Hierarchical temporal processing deficit model of reality distortion and psychoses.
-
High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.
-
Hospitalized schizophrenic patient views about seclusion.
-
How specific are negative symptoms and cognitive impairment in schizophrenia? An analysis of PANSS and SCoRS.
-
Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial.
-
Impact of obesity on health-related quality of life in schizophrenia and bipolar disorder.
-
Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.
-
Implementation considerations for multisite clinical trials with cognitive neuroscience tasks.
-
In the eye of the beholder: Perceptions of neighborhood adversity and psychotic experiences in adolescence.
-
Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients.
-
Initial level of care and clinical status in a managed mental health program.
-
Insight about psychosis among outpatients with schizophrenia.
-
Insight in schizophrenia and mania.
-
Insomnia is frequent in schizophrenia and associated with night eating and obesity.
-
Integrated genetic and genomic approach in the SingaporeTranslational and Clinical Research in Psychosis Study: an overview.
-
Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia.
-
Interview-based assessment of cognition in schizophrenia: applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care.
-
Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms.
-
Itemized clinician ratings versus global ratings of symptom severity in patients with schizophrenia.
-
L-dopa challenge and relapse in schizophrenia.
-
Latent structure of cognition in schizophrenia: a confirmatory factor analysis of the MATRICS Consensus Cognitive Battery (MCCB).
-
Letter to the editor: Critique of Bahorik et al. (2013)--'Under-reporting of drug use among individuals with schizophrenia: prevalence and predictors'.
-
Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.
-
MRI changes in schizophrenia in late life: a preliminary controlled study.
-
Machine learning approach to measurement of criticism: The core dimension of expressed emotion.
-
Measuring memory-prediction errors and their consequences in youth at risk for schizophrenia.
-
Measuring outcome priorities and preferences in people with schizophrenia.
-
Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care.
-
Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives.
-
Memory for prose in Korsakoff and schizophrenic populations.
-
Memory-prediction errors and their consequences in schizophrenia.
-
Methodological issues in negative symptom trials.
-
Neural bases of different cognitive strategies for facial affect processing in schizophrenia.
-
Neural correlates of automatic and controlled auditory processing in schizophrenia.
-
Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia.
-
Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
-
Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function.
-
Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study.
-
Neuropsychological decline in schizophrenia from the premorbid to the postonset period: evidence from a population-representative longitudinal study.
-
Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia.
-
Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: prospective birth cohort study.
-
Neuropsychological profile in adult schizophrenia measured with the CMINDS.
-
Neuropsychological status of subjects at high risk for a first episode of psychosis.
-
Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis.
-
Normal smooth pursuit eye movements in volunteer subjects meeting schizotypal personality disorder criteria.
-
Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS).
-
Observable Social Cognition--A Rating Scale: an interview-based assessment for schizophrenia.
-
Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
-
On Thoughts, Threats, and Throwing the Spear.
-
Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.
-
Overconfidence in false autobiographical memories in patients with schizophrenia.
-
Partial REM sleep deprivation, schizophrenia and field articulation.
-
Patient-Informed Treatment Development of Behavioral Smoking Cessation for People With Schizophrenia.
-
Performance of a weight-related measure of Quality of Life in a psychiatric sample.
-
Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests.
-
Performance of patients with schizophrenia on a pen and paper visuospatial working memory task with short delay.
-
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
-
Pharmacotherapy of impaired affect in recovering schizophrenic patients.
-
Placebo Response and Practice Effects in Schizophrenia Cognition Trials.
-
Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: a preliminary study.
-
Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls.
-
Polygenic risk score, genome-wide association, and gene set analyses of cognitive domain deficits in schizophrenia.
-
Predicting Schizophrenia.
-
Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial.
-
Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.
-
Predictors of therapeutic response to haloperidol in acute schizophrenia.
-
Premorbid sociosexual functioning and long-term outcome in schizophrenia.
-
Principal components of heritability from neurocognitive domains differ between families with schizophrenia and control subjects.
-
Proof-of-concept randomized controlled trial of pregnenolone in schizophrenia.
-
Psychometric characteristics of the MATRICS Consensus Cognitive Battery in a large pooled cohort of stable schizophrenia patients.
-
Psychoneuroendocrinology of schizophrenia.
-
Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia.
-
Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an α7 Nicotinic Acetylcholine Receptor Agonist, as a Treatment for Cognitive Impairment in Schizophrenia.
-
Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone.
-
Refining the latent structure of neuropsychological performance in schizophrenia.
-
Relationship of cognition and psychopathology to functional impairment in schizophrenia.
-
Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia.
-
Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.
-
Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale.
-
Religious coping and quality of life among individuals living with schizophrenia.
-
Report from the working group conference on multisite trial design for cognitive remediation in schizophrenia.
-
Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia.
-
Response to Bora.
-
Revisiting the backward masking deficit in schizophrenia: individual differences in performance and modeling with transcranial magnetic stimulation.
-
Risks versus benefits of different types of long-acting injectable antipsychotics.
-
Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence.
-
Schizophrenia is a cognitive illness: time for a change in focus.
-
Schizophrenia is a disorder of higher order hierarchical processing.
-
Schizophrenic-like neurocognitive deficits in children and adolescents with 22q11 deletion syndrome.
-
Self-reported sleep disturbances associated with procedural learning impairment in adolescents at ultra-high risk for psychosis.
-
Severity of symptoms in chronically institutionalized geriatric schizophrenic patients.
-
Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
-
Social functioning in urban, predominantly African American, socially disadvantaged patients with first-episode nonaffective psychosis.
-
Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis.
-
Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications.
-
Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls.
-
Spectral and topographic analysis of EEG in schizophrenic patients.
-
Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States.
-
Standardizing the use of the Continuous Performance Test in schizophrenia research: a validation study.
-
Static and dynamic cognitive deficits in childhood preceding adult schizophrenia: a 30-year study.
-
Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
-
Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study.
-
Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study.
-
The Brief Adherence Rating Scale (BARS) validated against electronic monitoring in assessing the antipsychotic medication adherence of outpatients with schizophrenia and schizoaffective disorder.
-
The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery.
-
The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition.
-
The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later?
-
The G72/G30 gene complex and cognitive abnormalities in schizophrenia.
-
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
-
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.
-
The Schizophrenia Cognition Rating Scale: an interview-based assessment and its relationship to cognition, real-world functioning, and functional capacity.
-
The Schizophrenia Cognition Rating Scale: validation of an interview-based assessment of cognitive functioning in Asian patients with schizophrenia.
-
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
-
The boundaries of schizophrenia.
-
The continuous performance test, identical pairs: norms, reliability and performance in healthy controls and patients with schizophrenia in Singapore.
-
The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
-
The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial.
-
The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis.
-
The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial.
-
The influence of emotional distraction on verbal working memory: an fMRI investigation comparing individuals with schizophrenia and healthy adults.
-
The intricate link between violence and mental disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
-
The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies.
-
The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine.
-
The targets of violence committed by young offenders with alcohol dependence, marijuana dependence and schizophrenia-spectrum disorders: findings from a birth cohort.
-
Twin studies of psychopathology: why do the concordance rates vary?
-
Understanding symbol coding in schizophrenia.
-
Unirhinal olfactory function in schizophrenia patients and first-degree relatives.
-
Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives.
-
Unraveling interrelationships among psychopathology symptoms, cognitive domains and insight dimensions in chronic schizophrenia.
-
Unraveling the relationship between obesity, schizophrenia and cognition.
-
Using discriminant function analysis with clinical, demographic and historical variables to diagnose schizophrenia.
-
Validation of the French version of the BACS (the brief assessment of cognition in schizophrenia) among 50 French schizophrenic patients.
-
Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results.
-
Validation of the Persian version of the brief assessment of cognition in schizophrenia in patients with schizophrenia and healthy controls.
-
Validation of the tablet-administered Brief Assessment of Cognition (BAC App).
-
Validity and reliability of the Brazilian Portuguese version of the BACS (Brief Assessment of Cognition in Schizophrenia).
-
Violent behavior in mental illness: the role of substance abuse.
-
Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes.
-
Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning.
-
White matter abnormalities and neurocognitive deficits associated with the passivity phenomenon in schizophrenia: a diffusion tensor imaging study.
-
Wisconsin Card Sorting Test performance in schizophrenia: the role of working memory.
-
Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment.
-
rTMS strategies for the study and treatment of schizophrenia: a review.